[1] Fisher B. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primarybreast cancer[J]. Cancer, 1977, 40(S1): 574-587.
[2] Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: An overview of the randomized trails[J]. New England Journal of Medicine, 1995, 333(22): 1444-1455.
[3] Reintgen C, Reintgen D, Solin L J. Advances in local-regional treatment for patients with early- stage breast cancer: A review of the field[J]. Clinical Breast Cancer, 2010, 10(3): 180-187.
[4] 王立泽, 欧阳涛, 王天峰, 等. 乳腺癌保乳治疗后局部复发的临床研究[J]. 中华外科杂志, 2010, 48(24): 1851-1854. Wang Lize, Ouyang Tao, Wang Tianfeng, et al. Clinical research on local relapses after breast conserving therapy of breast cancer[J]. Chinese Journal of Surgery, 2010, 48(24): 1851-1854.
[5] Fortin A, Larochelle M, Laverdiere J, et al. Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy[J]. Journal of Clinical Oncology, 1999, 17(1): 101-109.
[6] Khan S A, Eladoumikdachi F. Optimal Surgical treatment of breast cancer: Implications for local control and survival[J]. Journal of Surgical Oncology, 2010, 101(8): 677-686.
[7] Fisher B, Anderson S, Bryant J, et al. Twenty- year follow- up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer[J]. New England Journal of Medicine, 2002, 347(16): 1233-1241.
[8] Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast- conserving surgery with radical mastectomy for early breast cancer[J]. New England Journal of Medicine, 2002, 347(16): 1227-1232.
[9] Litière S, Werutsky G, Fentiman I S, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial[J]. Lancet Oncology, 2012, 13(4): 412-419.
[10] Katipamula R, Degnim A C, Hoskin T, et al. Trends in mastectomy rates at the Mayo Clinic Rochester: Eeffect of surgical year and preoperative magnetic resonance imaging[J]. Journal of Clinical Oncology, 2009, 27(25): 4082-4088.
[11] Plana M N, Carreira C, Muriel A, et al. Magnetic resonance imaging in the preoperative assessment of patients with primary breast cancer: Systematic review of diagnostic accuracy and meta- analysis[J]. European Radiology, 2012, 22(1): 26-38.
[12] Solin L J, Orel S G, Hwang W T, et al. Relationship of breast magnetic resonance imaging to outcome after breast- conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ[J]. Journal of Clinical Oncology, 2008, 26(3): 386-391.
[13] Moran M S, Schnitt S J, Giuliano A E, et al. Society of Surgical Oncology American Society for radiation oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages i and ii invasive breast cancer[J]. International Journal of Radiation Oncology, Biology, Physics, 2014, 88(3): 553- 564.
[14] Petrek J A, Senie R T, Peters M, et al. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis[J]. Cancer, 2001, 92(6): 1368-1377.
[15] Krag D N, Weaver D L, Alex J C, et al. Surgical resection and radiolocalization of the sentinal lymph node in breast cancer using a gamma probe[J]. Surgical Oncology, 1993, 2(6): 335-339.
[16] Mansel R E, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial[J]. Journal of the National Cancer Institute , 2006, 98(9): 599-609.
[17] Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer[J]. New England Journal of Medicine, 2003, 349(6): 546-553.
[18] Krag D N, Anderson S J, Julian T B,et al. Sentinel- lymph- node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial[J]. Lancet Oncology, 2010, 11(10): 927–933.
[19] Giuliano A E, Hunt K K, Ballman K V, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis[J]. Journal of the American Medical Association, 2011, 305(6): 569–575.
[20] Goldhirsch A，Wood W C, Coates A S, et al. Strategies for subtypes— dealing with the diversity of breast cancer: Highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2011[J]. Annals of Oncology, 2011, 22(8): 1736-1747.
[21] Lyman G H, Temin S, Edge S B, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American society of clinical oncology clinical practice guideline update[J]. Journal of Clinical Oncology, 2014, 32(13): 1365-1383.
[22] Mamounas E P, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from national surgical adjuvant breast and bowel project protocol B-27[J]. Journal of Clinical Oncology, 2005, 23(12): 2694-2702.
[23] Hunt K K, Yi M, Mittendorf E A, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients[J]. Annals of Surgery, 2009, 250(4): 558-566.
[24] Kelly A M, Dwamena B, Cronin P, et al. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapysystematic review and meta analysis[J]. Academic Radiology, 2009, 16(5): 551-563.
[25] Alvarado R, Yi M, Le-Petross H, et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer[J]. Annals of Surgical Oncology, 2012, 19(10): 3177-3184.
[26] Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): A prospective, multicentre cohort study[J]. Lancet Oncology, 2013, 14(7): 609-618.
[27] Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel lymph node biopsy before or after neoadjuvant chemotherapy final results from the prospective, German multiinstitutional SENTINA trial[C]. San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 4-8, 2012.
[28] Jagsi R, Jiang J, Momoh A O, et al. Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the United States[J]. Journal of Clinical Oncology, 2014, 32(9): 919-926.
[29] Perou C M, Sorlie T, Eisen M B, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797): 747-752.
[30] Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets[J]. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100(14): 8418-8423.
[31] Yamamoto Y, Ibusuki M, Nakano M, et al. Clinical significance of basal-like subtype in triple-negative breast cancer[J]. Breast Cancer, 2009, 16(4): 260-267.
[32] Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinicalbenefi t in breast cancer: The CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172.
[33] Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the Gepar Quattro study[J]. Journal of Clinical Oncology, 2010, 28(12): 2024- 2031.
[34] Ollila D W, Berry D A, Cirrincione C, et al. Impact of neoadjuvant chemotherapy plus HER2- targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance)[J]. Journal of Clinical Oncology, 2013, 31(S15): 501.
[35] Harbeck N. American Society of Clinical Oncology highlights 2013: Breast cancer and gynecological malignancies[J]. Future Oncology, 2013, 9(10): 1433-1436.
[36] Gianni L, Eiermann W, Semiglazov V, et al. Follow- up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT + H) followed by adjuvant H, versus CT alone, in patients with HER- 2 positive locally advanced breast cancer[J]. Journal of Clinical Oncology, 2013, 31(S15): 503.
[37] Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone- receptor- positive advanced breast cancer[J]. New England Journal of Medicine, 2012, 336(6): 520-529.
[38] O'Regan R, Ozguroglu M, Andre F, et al. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab- resistant, advanced breast cancer (BOLERO-3)[J]. Journal of Clinical Oncology, 2013, 31(S15): 505.
